Aim of the study: The coronavirus disease 2019 (COVID-19) pandemic significantly impacted cancer care. In this study, clinical patient characteristics related to COVID-19 outcome and advanced care planning, in terms of non-oncological treatment restrictions (e.g., do-not-resuscitate codes), were studied in patients with cancer and COVID-19.
Methods
The Dutch Oncology COVID-19 Consortium (DOCC) registry was launched in March 2020 in 45 hospitals in the Netherlands, primarily to identify risk factors of a severe COVID-19 outcome in patients with cancer. Here, an updated analysis of the registry was performed, and treatment restrictions (e.g., do-not-intubate codes) were studied in relation to COVID-19 outcome in patients with cancer. Oncological treatment restrictions were not taken into account.
Results
Between March 27
th
, 2020, and February 4
th
, 2021, 1360 patients with cancer and COVID-19 were registered. Follow-up data of 830 patients could be validated for this analysis. Overall, 230 out of 830 (27.7%) patients died of COVID-19, and 60% of the remaining 600 patients with resolved COVID-19 were admitted to the hospital. Patients with haematological malignancies or lung cancer had a higher risk of a fatal outcome than other solid tumours. No correlation between anti-cancer therapies and the risk of a fatal COVID-19 outcome was found. In terms of end-of-life communication, 50% of all patients had restrictions regarding life-prolonging treatment (e.g., do-not-intubate codes). The majority of the identified patients with treatment restrictions had risk factors associated with fatal COVID-19 outcome.
Conclusion
There was no evidence of a negative impact of anti-cancer therapies on COVID-19 outcome. Timely end-of-life communication as part of advanced care planning could save patients from prolonged suffering and decrease burden in intensive care units. Early discussion of treatment restrictions should therefore be part of routine oncological care, especially during the COVID-19 pandemic.